Figure 3.

GSK690/JNJ-26481585 cotreatment alters the balance between pro- and antiapoptotic proteins. (a-d) Cells were treated for indicated times with 1 μM GSK690 (RD cells) or 10 μM GSK690 (RH30 cells) and/or 15 nM JNJ-26481585. Expression levels of BMF, BIM, NOXA, and PUMA mRNA were analyzed by qRT-PCR and fold changes relative to untreated control of each time point are shown with mean and S.D. of three independent experiments performed in duplicate; *P<0.05; **P<0.01; ***P<0.001; ns, not significant. (e) Cells were treated for 6 h with 1 μM GSK690 (RD cells) or 10 μM GSK690 (RH30 cells) and/or 15 nM JNJ-26481585. Protein levels of BMF (20 and 25 kDa), BIM and NOXA were detected by Western blotting. β-Actin was used as loading control. (f) Cells were treated for 9 h with 1 μM GSK690 (RD cells) or 10 μM GSK690 (RH30 cells) and/or 15 nM JNJ-26481585. Protein levels of PUMA were detected by Western blotting. GAPDH and β-Actin were used as loading controls. Asterisks indicate unspecific bands